Efficacy and Safety of Nerandomilast in Patients with Autoimmune-Interstitial Lung Disease (ILD) and Progressive Pulmonary Fibrosis in Subgroups by Time Since ILD Diagnosis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1617; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
|